Benefits
Post-myocardial infarction heart failure
Statsenko ME et al. 2014 — post-MI heart failure RCT in 60 patients. Meldonium 1,000 mg/day IV for 10-14 days as adjunct to standard post-MI management. Cardiovascular function and metabolic parameter improvements consistent with the fatty-acid-to-glucose oxidation shift mechanism.
Peripheral arterial disease / claudication
Skarda 2011 (Semin Cardiovasc Med) — Western RCT in peripheral arterial disease. Mildronate 1,000 mg/day for 24 weeks significantly improved exercise tolerance in claudication patients. One of the few non-Russian-language meldonium clinical trials, supporting Western-population generalizability for the PAD indication.
Stable angina (multiple Russian RCTs)
Multiple smaller Russian RCTs in stable angina pectoris. Honest framing: per review, 'all published clinical efficacy studies on meldonium, except one, are in Russian' — this is a substantial methodological access limitation for Western evidence assessment.
Cerebral ischemia / acute stroke (Phase II)
Phase II acute ischemic stroke trial provided initial cerebrovascular evidence. Approved indication in CIS countries for cerebrovascular disease and acute ischemia adjunct treatment.
Diabetic neuropathy adjunct
Approved indication in CIS countries for diabetic peripheral neuropathy — leveraging the cardiovascular and microcirculatory effects to support nerve-tissue protection in diabetes.
WADA prohibition + Sharapova case (regulatory context)
Added to WADA Prohibited List January 1, 2016 based on cited 'potential performance enhancement' — a controversial decision. March 2016: Maria Sharapova publicly admitted use, lost 2016 Australian Open results, received 15-month suspension — the most prominent meldonium WADA case. Other athletes also tested positive (Pavel Kulizhnikov, Eduard Vorganov, Ukrainian biathletes). April 2016 WADA u-turn admitted uncertainty about meldonium body persistence; many low-concentration positives reflected pre-ban use, and most cases were dropped except Sharapova's (high concentration confirmed continued use).
Mechanism of action
γ-butyrobetaine hydroxylase inhibition (carnitine biosynthesis blocker)
Meldonium (3-(2,2,2-trimethylhydrazine)propionate dihydrate; CAS 76144-81-5) is a competitive inhibitor of γ-butyrobetaine hydroxylase — the enzyme that converts γ-butyrobetaine to L-carnitine. The inhibition reduces carnitine biosynthesis, which in turn reduces fatty acid mitochondrial transport. Mechanistically distinct from cardioactive drugs that act on adrenergic, calcium-channel, or RAAS pathways.
Cardiac metabolism shift: fatty acid → glucose oxidation
Reduced fatty acid mitochondrial transport shifts cardiac energy metabolism from fatty acid oxidation (oxygen-intensive) to glucose oxidation (more oxygen-efficient — produces more ATP per unit oxygen consumed). Restores energy production efficiency under ischemic or hypoxic conditions where oxygen supply is limited. The proposed cardiac protection mechanism.
Increased glucose uptake
Downstream effect of the metabolism shift — increased glucose uptake into cardiomyocytes supports the glucose-oxidation pathway and improves substrate utilization during ischemic stress.
Endothelial function improvement
Endothelial NO production improvement contributes to the cardiovascular and microcirculatory benefits — relevant to PAD, diabetic neuropathy, and cerebrovascular indications.
Peroxisome activity increase
Increased peroxisome activity contributes to fatty acid metabolism redirection — peroxisomes handle very-long-chain fatty acid oxidation, providing alternative metabolic capacity beyond mitochondrial fatty acid β-oxidation.
Neuroprotective effects in cerebral ischemia
The same metabolic shift mechanisms that protect cardiomyocytes during ischemia apply to neurons during cerebral ischemia — underlying the cerebrovascular and stroke indications.
Clinical trials
Clinical evidence on Mildronate (Meldonium) for the indications and outcomes described.
60 patients
Statsenko ME et al. 2014. Post-MI heart failure clinical trial in 60 patients. Meldonium 1,000 mg/day IV for 10-14 days as adjunct to standard management. Cardiovascular function and metabolic parameter improvements consistent with the fatty-acid-to-glucose oxidation shift mechanism.
(Semin Cardiovasc Med).
Clinical population described in trial publication.
(Semin Cardiovasc Med). Western clinical trial in peripheral arterial disease. Mildronate 1,000 mg/day for 24 weeks significantly improved exercise tolerance. One of the few non-Russian-language meldonium clinical trials supporting Western-population generalizability for PAD.
Added to WADA Prohibited List January 1, 2016.: Maria Sharapova admitted use, 15-month suspension.
Clinical population described in trial publication.
Added to WADA Prohibited List January 1, 2016.: Maria Sharapova admitted use, 15-month suspension. WADA u-turn admitted uncertainty about body persistence — many low-concentration positives reflected pre-ban use; most cases dropped except Sharapova's. Reflects regulatory ambiguity rather than a clear-cut performance-enhancement determination.